ID

20107

Description

Study of Breast Cancer Prevention by Letrozole in High Risk Women; ODM derived from: https://clinicaltrials.gov/show/NCT00579826

Lien

https://clinicaltrials.gov/show/NCT00579826

Mots-clés

  1. 06/02/2017 06/02/2017 -
Téléchargé le

6 février 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0

Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Groupe Item commentaires pour :

Item commentaires pour :


Aucun commentaire

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Breast Cancer NCT00579826

Eligibility Breast Cancer NCT00579826

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
post-menopausal women at high risk for development of breast cancer
Description

Post-menopausal: high risk for breast cancer

Type de données

boolean

Alias
UMLS CUI [1,1]
C0232970
UMLS CUI [1,2]
C4047809
on a stable dose of hormone replacement therapy
Description

Hormone replacement therapy

Type de données

boolean

Alias
UMLS CUI [1]
C0282402
have cytomophologic evidence of hyperplasia +/- atypia and ki-67 expression >1.5% in benign breast epithelial cells acquired by rpfna
Description

Rpfna: Cytology

Type de données

boolean

Alias
UMLS CUI [1,1]
C3640066
UMLS CUI [1,2]
C0010819
serum level of 25-oh vitamin d of at least 30 ng/ml prior to study entry
Description

25-oh vitamin d level

Type de données

boolean

Alias
UMLS CUI [1]
C1255280
willing to have a repeat rpfna and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug
Description

Willing to participate

Type de données

boolean

Alias
UMLS CUI [1,1]
C0600109
UMLS CUI [1,2]
C2348568
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior history of osteoporosis or osteoporotic fracture.
Description

Osteoporosis or osteoporotic fracture

Type de données

boolean

Alias
UMLS CUI [1]
C0521170
prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.
Description

Invasive breast cancer

Type de données

boolean

Alias
UMLS CUI [1]
C0853879
current and chronic use of cox-2 specific inhibitors or nsaids
Description

Cox-2 specific inhibitors or nsaids

Type de données

boolean

Alias
UMLS CUI [1]
C1257954
UMLS CUI [2]
C0003211
receiving treatment for rheumatoid arthritis or fibromyalgia
Description

Treatment for rheumatoid arthritis or fibromyalgia

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0003873
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C0016053
current history of poorly controlled migraines or perimenopausal symptoms
Description

Migraines or perimenopausal symptoms

Type de données

boolean

Alias
UMLS CUI [1]
C0149931
UMLS CUI [2]
C0949062
currently receiving other investigational agents.
Description

Investigational agents

Type de données

boolean

Alias
UMLS CUI [1]
C1875319
receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past.
Description

Aromatase inhibitor

Type de données

boolean

Alias
UMLS CUI [1]
C0593802

Similar models

Eligibility Breast Cancer NCT00579826

Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Post-menopausal: high risk for breast cancer
Item
post-menopausal women at high risk for development of breast cancer
boolean
C0232970 (UMLS CUI [1,1])
C4047809 (UMLS CUI [1,2])
Hormone replacement therapy
Item
on a stable dose of hormone replacement therapy
boolean
C0282402 (UMLS CUI [1])
Rpfna: Cytology
Item
have cytomophologic evidence of hyperplasia +/- atypia and ki-67 expression >1.5% in benign breast epithelial cells acquired by rpfna
boolean
C3640066 (UMLS CUI [1,1])
C0010819 (UMLS CUI [1,2])
25-oh vitamin d level
Item
serum level of 25-oh vitamin d of at least 30 ng/ml prior to study entry
boolean
C1255280 (UMLS CUI [1])
Willing to participate
Item
willing to have a repeat rpfna and mammogram at 6 months and 12 months (if participating in the open label portion of the study) following initiation of study drug
boolean
C0600109 (UMLS CUI [1,1])
C2348568 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Osteoporosis or osteoporotic fracture
Item
prior history of osteoporosis or osteoporotic fracture.
boolean
C0521170 (UMLS CUI [1])
Invasive breast cancer
Item
prior history of invasive breast cancer or other invasive cancer within five years from date of study entry.
boolean
C0853879 (UMLS CUI [1])
Cox-2 specific inhibitors or nsaids
Item
current and chronic use of cox-2 specific inhibitors or nsaids
boolean
C1257954 (UMLS CUI [1])
C0003211 (UMLS CUI [2])
Treatment for rheumatoid arthritis or fibromyalgia
Item
receiving treatment for rheumatoid arthritis or fibromyalgia
boolean
C0087111 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C0016053 (UMLS CUI [2,2])
Migraines or perimenopausal symptoms
Item
current history of poorly controlled migraines or perimenopausal symptoms
boolean
C0149931 (UMLS CUI [1])
C0949062 (UMLS CUI [2])
Investigational agents
Item
currently receiving other investigational agents.
boolean
C1875319 (UMLS CUI [1])
Aromatase inhibitor
Item
receipt of more than 6 months of an aromatase inhibitor (anastrozole, exemestane, letrozole, etc.) at any time in the past.
boolean
C0593802 (UMLS CUI [1])

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial